Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-06

Clinical Trial Update: Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial [Phase 2, Phase 3]

View source ↗

Summary

Adaptive trial evaluating selepressin for sepsis-induced shock was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Selepressin (selepressin)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Septic Shock | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-04-06